



Funds Range Information International

2025/09/25

Please find below the latest modifications to the CANDRIAM funds range.

The list of ISINs and links for documents to our Candriam site are available in the attached excel file.



Luxembourg

Notice to shareholders - New prospectus

The new prospectus of **Candriam Equities L** will enter into force on the **20th of October 2025** with the following changes:

- **Update** of the **applicable exclusion policy** for **Candriam Equities L Europe Innovation and Candriam Equities L Europe Optimum Quality**
- **Candriam Equities L Europe Innovation** and **Candriam Equities L Oncology** obtained the French “**Label ISR**”, on the other hand, **Candriam Equities L Europe Optimum Quality** lost it
- **Renaming** of the following **Candriam Equities L Oncology** share classes following **hedging change**:

ISIN	Old name	New name
LU2015348795	S-JPY-Asset Hedged-Cap	S-JPY-Hedged-Cap
LU2015349090	S-JPY-Asset Hedged-Dis	S-JPY-Hedged-Dis

- **Update of the PCDs** (except for **Candriam Equities L Oncology**): **removal** of the **PAI 10** from the exclusion's perimeter.
- **Change** of the **volatility range** for **Candriam Equities L Risk Arbitrage Opportunities**

Notice to shareholders	Yes	No	Distribution date
Press information		•	
Individual letter to registered shareholders	•		15/09/2025



France

Notice to shareholders - New prospectus

The new prospectus of **Candriam Index Arbitrage** will enter into force on the **26th of September 2025** with the following changes:

- **Fiscal year-end modification**: September → **December**
- **Alignment** of **crystallization** of the **performance fees** with the **end of the fiscal year**
- More info on **personal data** treatment by **NYLIM**

Notice to shareholders	Yes	No	Distribution date
Press information		•	
Individual letter to registered shareholders	•		17/09/2025

2025/09/25

This document is published solely for the purposes of information for professional investors (as defined in the section "Legal Information" on our website www.candriam.com), distributors and intermediaries, it contains no offer for the purchase or sale of financial instruments, and it is not confirmation of any transaction unless expressly agreed otherwise. The information contained in this document was obtained from a number of different sources. Although CANDRIAM exercises the greatest care when choosing its sources of information and passing on this information, certain errors or omissions may have escaped our notice. The past performance of a product is by no means a guarantee of future results and the value of investments may increase or decrease. CANDRIAM cannot be held liable for any direct or indirect damage or loss resulting from the use of this document. The contents of this document may be reproduced only with the prior written agreement of CANDRIAM. The intellectual property rights of CANDRIAM must be respected at all times.

This recommendation is an advertising communication as defined in Article 24, §2 of Directive 2006/73/CE dated 10 August 2006 executing Directive 2004/39/CE of the European Parliament and Council. It has not been drawn up in accordance with the legal provisions intended to promote the independence of investment research, and it is not subject to any prohibition of transactions prior to the dissemination of investment research.